Doxorubicin cardiomyopathy

Cardiology. 2010;115(2):155-62. doi: 10.1159/000265166. Epub 2009 Dec 11.


Established doxorubicin cardiomyopathy is a lethal disease. When congestive heart failure develops, mortality is approximately 50%. Extensive research has been done to understand the mechanism and pathophysiology of doxorubicin cardiomyopathy, and considerable knowledge and experience has been gained. Unfortunately, no effective treatment for established doxorubicin cardiomyopathy is presently available. Extensive research has been done and is being done to discover preventive treatments. However an effective and clinically applicable preventive treatment is yet to be discovered.

Publication types

  • Review

MeSH terms

  • Antibiotics, Antineoplastic / adverse effects*
  • Cardiomyopathies / chemically induced*
  • Cardiomyopathies / diagnosis
  • Cardiomyopathies / pathology
  • Cardiomyopathies / therapy
  • Doxorubicin / adverse effects*
  • Humans
  • Myocardium / pathology


  • Antibiotics, Antineoplastic
  • Doxorubicin